Union Product Database (UPD) Access Policy
Veterinary Medicinal Products

POLICY/no    0082
Status:      Public
Effective date: 1 August 2024
Review date: 1 August 2027
Supersedes: EMA/198149/2020
Table of contents

1. Introduction and purpose ................................................................. 3
2. Scope ............................................................................................ 3
3. Policy statement .............................................................................. 4
   3.1. Union Product Database .............................................................. 4
   3.2. Access to Union Product Database .............................................. 5
       3.2.1. Stakeholder groups ............................................................... 5
       3.2.2. General principles ............................................................... 5
       3.2.3. Personal Data Protection ...................................................... 6
       3.2.4. Methods of providing access to veterinary medicinal product information held in UPD 7
       3.2.5. Detailed description of access to veterinary medicinal product data held in UPD, by Stakeholder .......................................................... 8
4. Related documents .......................................................................... 10
5. Changes since last revision ............................................................. 10
Annex A – Product data elements accessible by stakeholder group .......... 12
1. Introduction and purpose

The European Medicines Agency (hereafter referred to as “the Agency”) and the Member States’ competent authorities collectively comprise the European Union (EU) regulatory network. The network’s responsibilities are the protection and promotion of public and animal health and the environment through the evaluation and supervision of medicines.

Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC (‘the VMP Regulation’), was adopted on 11 December 2018, entered into force on 28 January 2019 and became applicable from 28 January 2022, following a 3-year implementation period. The VMP Regulation contains new measures for increasing the availability and safety of veterinary medicines, enhances EU action against antimicrobial resistance and will modernise the existing rules on the authorisation and use of veterinary medicines in the EU.

The VMP Regulation mandates that the Agency establish and, in collaboration with the Member States, maintain, a Union database on veterinary medicinal products (UPD), containing information on veterinary medicinal products authorised within the Union, homeopathic veterinary medicinal products registered within the Union, veterinary medicinal products exempted in a Member State from the marketing authorisation requirements, and parallel traded products. This database shall also register the annual volume of sales, information on the availability for each veterinary medicinal product and variations not requiring assessment for authorised veterinary medicinal products.

Commission Implementing Regulation (EU) 2021/16 of 8 January 2021 laying down the necessary measures and practical arrangements for the Union database on veterinary medicinal products details the specifications to implement in order to fulfil the requirements of the VMP Regulation. In this context, it was mandated that a detailed access policy be drawn up and applied by the Agency, in collaboration with the competent authorities and the European Commission, and in consultation with marketing authorisation holders, before the UPD became operational. The policy enables actors to perform their obligations as provided for in the VMP Regulation, while protecting commercially confidential information and personal data. It therefore provides different levels of access to the UPD processes. The first version of the policy (EMA/198149/2020) was adopted on 25 January 2021.

2. Scope

This Access Policy defines the overall principles for providing access to veterinary medicinal product information held in the UPD in line with the EU legislative framework, considering that the interest in and the use of the data may vary between stakeholders.

The policy has been drafted with the aim of providing transparency and visibility of information on veterinary medicinal products while protecting commercially confidential information in accordance with Regulation (EC) No 1049/2001. Requirements to protect personal data based on Regulation (EU) 2016/679 and Regulation (EU) 2018/1725 are reflected in the policy accordingly.

‘Veterinary medicinal products’ in this policy include

- authorised veterinary medicinal products;
- registered homeopathic veterinary medicinal products;
- veterinary medicinal products exempted in a Member State from the marketing authorisation requirements under Article 5(6); and
- parallel traded products.
The VMP Regulation defines the level of UPD access as follows (Article 56):

1. *The competent authorities, the Agency and the Commission shall have full access to the information in the product database.*

2. *Marketing authorisation holders\(^1\) shall have full access to the information in the product database as regards their marketing authorisations.*

3. *The general public shall have access to information in the product database, without the possibility to change the information therein, as regards the list of the veterinary medicinal products, the summary of product characteristics, package leaflets and, after the deletion of any commercially confidential information by the competent authority, the assessment reports.*

The description of individual scenarios and veterinary medicinal products are further outlined in Annex A.

### 3. Policy statement

This Access Policy has been developed with the goal of facilitating the maintenance of and accessibility to information on veterinary medicinal products in the EU, within the overall aim of promoting and protecting animal and public health and the environment.

Furthermore, this Access Policy aims to meet the EU principles of transparency and openness while ensuring compliance with EU personal data protection legislation. The following objectives should be met, by providing proactive access to product information on veterinary medicinal products:

1. Increasing availability of and access to information on veterinary medicinal products authorised to treat and prevent animal diseases in the EU for veterinarians, farmers and pet owners and any other interested parties;

2. Supporting the functioning of the internal EU market for veterinary medicinal products;

3. Improving transparency of veterinary medicinal products used in the EU;

4. Strengthening the decision making for the European Commission, competent authorities and marketing authorisation holders by providing access to data analytics and reports;

5. Simplifying the regulatory environment and reducing the administrative burden by giving marketing authorisation holders and competent authorities access to the functionalities of the variations without assessment module of the UPD.

### 3.1. Union Product Database

The UPD comprises a range of functions required for the administration and quality management of information related to veterinary medicinal products and its secure electronic transmission. Additionally, the UPD offers a specific mechanism for handling a change to the data that occurs when such changes are based on a variation that does not require assessment. A set of components has been designed, enhanced or reutilised to support such functionalities:

- **Access management component** which manages the control of access to data or functionalities and ensures that all stakeholders have the appropriate access to the resources provided by the UPD and the proper permissions to perform actions in the UPD.

---

\(^1\) ‘Marketing authorisation holder’ is defined in this policy to include: holder of the marketing authorisation for a veterinary medicinal product, of the registration for a homeopathic veterinary medicinal product or of the exemption for products allowed for use in accordance with Article 5(6) of Regulation (EU) 2019/6
• **Data and document submission component** which manages the requests for submission to the UPD of data and documents relating to new veterinary medicinal products in order to create a new dataset, variations and other post-authorisation changes to the datasets already existing in the UPD for veterinary medicinal products.

• **Application programming interface (API)**\(^2\) for the exchange of data and documents with the systems used by marketing authorisation holders, competent authorities, the Agency, the European Commission and other general public registered users.

• **UPD portal** which, with the use of data publishing, data searching, viewing and exporting, as well as data analytics, presents information to users and makes certain features available to them in accordance with their access rights (objective 4).

• **Data and document repository component** which manages all data and documents that enter into the UPD.

• **Component to manage variations that do not require assessment** which allows the marketing authorisation holder to record a variation that does not require assessment and allows the relevant competent authority or the European Commission, as applicable, to be notified and to approve or reject such variations prior to the update in the UPD, to update the dataset accordingly and to store and update related documentation (objective 5).

• **General public module** which is part of the UPD portal and allows the general public to search and view all publicly available data and documents on veterinary medicinal products referred to in Article 56 of the VMP Regulation (objectives 1, 2 and 3).

Different levels of access to these components must be defined and implemented to ensure that the different stakeholders interacting with the UPD can access the information necessary to fulfil their responsibilities as outlined in the VMP Regulation and related Implementing Acts or enjoy their right to access information.

### 3.2. Access to Union Product Database

#### 3.2.1. Stakeholder groups

The stakeholders being granted access to UPD data can be grouped as follows:

• **The European Commission, competent authorities**\(^3\) and the **Agency** including contractors and external service providers working for them on UPD related subjects;

• **Marketing authorisation holders**, including contractors and external service providers working for them on UPD related subjects;

• **General Public**: persons or organisations, other than the two groups referred to above, e.g. veterinary health care professionals and other interested persons.

#### 3.2.2. General principles

Veterinary medicinal products are recorded in the UPD as derived from legal obligations placed on competent authorities and marketing authorisation holders.

---

\(^2\) Access to and use of the API is subject to prior acceptance by the user of the EMA – API General Terms of Service – Terms of Use

\(^3\) Competent authorities as defined in Article 137 of Regulation (EU) 2019/6
The VMP Regulation gives the widest possible access to veterinary medicinal product data and to the related documents while protecting certain public and private interests, such as personal data and commercially confidential information in accordance with Regulation (EC) No 1049/2001.

The data elements for veterinary medicinal product data stored in the UPD are defined in the Commission Implementing Regulation (EU) 2021/16 of 8 January 2021 laying down the necessary measures and practical arrangements for the Union database on veterinary medicinal products (‘the Implementing Regulation’) and further detailed in the EU Implementation Guide on veterinary medicines product data in the Union Product Database (‘the EU Vet Implementation Guide’).

Access is defined based on the stakeholder’s interests and needs as well as the requirement to comply with EU personal data protection legislation (Regulation (EU) 2016/679 or General Data Protection Regulation (GDPR)). The protection of personal data is a fundamental right of Europeans. The access is further defined at different levels considering that due to the nature of the information not all data elements can be disclosed to avoid identification of data subjects or dissemination of commercially confidential information.

Annex A lists all UPD veterinary medicinal product data elements and outlines which can be accessed by the different stakeholder groups, based on the access levels described in Table 1.

Table 1. Description of access levels

<table>
<thead>
<tr>
<th>Access Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 1</td>
<td>Public subset of veterinary medicinal product data elements with focus on the General Public user group.</td>
</tr>
<tr>
<td>Level 2</td>
<td>Extended subset of veterinary medicinal product data elements with focus on the marketing authorisation holder user group to fulfil their legal responsibilities for their own products, which have been recorded in the database by the authorities.</td>
</tr>
<tr>
<td>Level 3</td>
<td>All veterinary medicinal product data elements without restrictions with focus on the competent authorities, the European Commission and the Agency, taking into account their roles and responsibilities to protect public and animal health and the environment.</td>
</tr>
</tbody>
</table>

3.2.3. Personal Data Protection

The Agency, competent authorities and marketing authorisation holders are all responsible for ensuring confidentiality of veterinary medicinal product data and protecting personal data by implementing appropriate technical and organisational measures to protect information and personal data processed against unauthorised or unlawful access, disclosure, dissemination, alteration, or destruction or accidental loss in accordance with the applicable law on personal data protection.

Personal data shall mean any information relating to an identified or identifiable natural person (‘data subject’); an identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person; (Article 3(1) of Regulation (EU) 2018/1725).

For the Agency, the provisions set out in Regulation (EU) 2018/1725 apply; for competent authorities and marketing authorisation holders, the rules set out in Regulation (EU) 2016/679 (GDPR) apply.
3.2.4. Methods of providing access to veterinary medicinal product information held in UPD

Access to UPD data is provided through query and data retrieval functions based on the UPD system components described in section 3.1. Table 2 provides an overview of the UPD system components applied to provide access to UPD data for each stakeholder group and outlines the overall format of the data outputs.

<table>
<thead>
<tr>
<th>Stakeholder: the European Commission, competent authorities and the Agency</th>
<th>UPD System Component</th>
<th>Data Inputs</th>
<th>Data Outputs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data and document submission portal</td>
<td>Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)</td>
<td>Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)</td>
<td></td>
</tr>
<tr>
<td>Application programming interface</td>
<td>Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)</td>
<td>Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)</td>
<td></td>
</tr>
<tr>
<td>UPD portal</td>
<td>N/A</td>
<td>Web page(s) in HTML format; showing all product data and providing search functions</td>
<td></td>
</tr>
<tr>
<td>Management of variations not requiring assessment component</td>
<td>Approvals/Rejections</td>
<td>Web pages in HTML format</td>
<td></td>
</tr>
<tr>
<td>Data and document repository component</td>
<td>Role Based Access Control (RBAC) will determine which structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)</td>
<td>Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stakeholder: Marketing authorisation holders</th>
<th>UPD System Component</th>
<th>Data Inputs</th>
<th>Data Outputs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data and document submission portal</td>
<td>Role Based Access Control (RBAC) will determine which structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)</td>
<td>Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)</td>
<td></td>
</tr>
<tr>
<td>Application programming interface</td>
<td>Role Based Access Control (RBAC) will determine which structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)</td>
<td>Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)</td>
<td></td>
</tr>
</tbody>
</table>
### UPD System Component

<table>
<thead>
<tr>
<th><strong>Data Inputs</strong></th>
<th><strong>Data Outputs</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>unstructured content (e.g. PDF)</td>
<td></td>
</tr>
</tbody>
</table>

### UPD portal

<table>
<thead>
<tr>
<th><strong>Data Inputs</strong></th>
<th><strong>Data Outputs</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>Web page(s) in HTML format; showing only data in accordance with their access rights and providing search functions</td>
</tr>
</tbody>
</table>

### Management of variations not requiring assessment component

<table>
<thead>
<tr>
<th><strong>Data Inputs</strong></th>
<th><strong>Data Outputs</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Structured electronic content</td>
<td>Web pages in HTML format</td>
</tr>
</tbody>
</table>

### Data and document repository component

<table>
<thead>
<tr>
<th><strong>Data Inputs</strong></th>
<th><strong>Data Outputs</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Role Based Access Control (RBAC) will determine which structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)</td>
<td>Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)</td>
</tr>
</tbody>
</table>

### Stakeholder: General public

<table>
<thead>
<tr>
<th><strong>Data Inputs</strong></th>
<th><strong>Data Outputs</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>Web page(s) in HTML format; showing only the subset of data that is available to the public and providing search functions</td>
</tr>
</tbody>
</table>

### Application programming interface

<table>
<thead>
<tr>
<th><strong>Data Inputs</strong></th>
<th><strong>Data Outputs</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)</td>
</tr>
</tbody>
</table>

### 3.2.5. Detailed description of access to veterinary medicinal product data held in UPD, by Stakeholder

#### 3.2.5.1. The European Commission, competent authorities and the Agency

#### 3.2.5.1.1. Veterinary medicinal products in UPD

In accordance with the VMP Regulation, the competent authorities, the Agency and the European Commission shall have full access to the information in the UPD.

**Table 3.** Access to UPD data by the competent authorities, the Agency and the European Commission

<table>
<thead>
<tr>
<th><strong>Stakeholder</strong></th>
<th><strong>Access Level</strong></th>
<th><strong>Access Type</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Competent authorities</td>
<td>UPD Level 3: All data elements for veterinary medicinal products reported to UPD (for details refer to Annex A)</td>
<td>Authorised personnel only</td>
</tr>
<tr>
<td>Agency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>European Commission</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contractors and external service providers working for the above authorities on the UPD subject</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
3.2.5.1.2. Methods of access

A description of how access is provided to these stakeholders including the main data outputs is given in Section 3.2.4.

3.2.5.1.3. Access authorisation

Access is granted to authorised personnel of the European Commission, the Agency and competent authorities. The identification of ‘authorised personnel’ is detailed in the UPD registration process described in the registration guide4. Contractors and external service providers are also considered “authorised personnel” and their access rights are administrated by the relevant organisation on whose behalf access is granted.

3.2.5.1.4. Personal data protection requirements

Data access and provision is based on a defined veterinary medicinal product data set (Level 3) in compliance with the VMP Regulation. A Data Protection Notice is included on the UPD Portal, explaining in detail how personal data are processed. The Agency is also operating a procedure for access and rectification in line with the aforementioned Regulation.

3.2.5.2. Marketing authorisation holders

3.2.5.2.1. Veterinary medicinal products in the UPD

In accordance with the VMP Regulation, the marketing authorisation holders shall have full access to the information in the UPD as regards their products.

Table 4. Access to UPD data by marketing authorisation holders

<table>
<thead>
<tr>
<th>Stakeholder</th>
<th>Access Level</th>
<th>Access Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Marketing Authorisation Holders</td>
<td>• UPD Level 2:</td>
<td>Authorised Personnel only</td>
</tr>
<tr>
<td>• Contractors and external service providers working for the above companies on the UPD subject</td>
<td>- Subset of data elements for veterinary medicinal products reported to UPD (for details refer to Annex A)</td>
<td></td>
</tr>
</tbody>
</table>

3.2.5.2.2. Methods of access

A description of how access is provided to these stakeholders including the main data outputs is given in Section 3.2.4.

3.2.5.2.3. Access authorisation

Access is granted to authorised personnel of the marketing authorisation holders. The identification of ‘authorised personnel’ is detailed in the UPD registration process described in the registration guide4. Contractors and external service providers are also considered “authorised personnel” and their access rights are administrated by the relevant organisation on whose behalf access is granted.

3.2.5.2.4. Personal data protection requirements

Data access and provision is based on a defined veterinary medicinal product data set (Level 2) in compliance with the VMP Regulation. A Data Protection Notice is included on the UPD Portal, explaining

4 UPD registration guide for veterinary medicinal products (europa.eu)
in detail how personal data are processed. The Agency is also operating a procedure for access and rectification in line with the aforementioned Regulation.

3.2.5.3. General public

3.2.5.3.1. Report of veterinary medicinal product

In accordance with the VMP Regulation, the general public shall have access to information in the UPD, without the possibility to change the information therein, as regards the list of the veterinary medicinal products, the summary of product characteristics, package leaflets and, after the deletion of any commercially confidential information by the competent authority, assessment reports.

Table 5. Access to UPD data by general public

<table>
<thead>
<tr>
<th>Stakeholder</th>
<th>Access Level</th>
<th>Access Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>General public</td>
<td>UPD Level 1: Subset of data elements for veterinary medicinal products reported to UPD (for details refer to Annex A)</td>
<td>Not required/controlled</td>
</tr>
</tbody>
</table>

3.2.5.3.2. Methods of access

A description of how access is provided to these stakeholders including the main data outputs is given in Section 3.2.4.

3.2.5.3.3. Access authorisation

No registration, authorisation or authentication shall be required to access the public interface of the UPD (Veterinary Medicines information website). Registration, authentication and authorisation will be required to access publicly available data via the Public API.

3.2.5.3.4. Personal data protection requirements

Data access and provision is based on a defined veterinary medicinal product data set (Level 1) in compliance with the VMP Regulation. A Data Protection Notice is included on the UPD Portal, explaining in detail how personal data are processed. The Agency is also operating a procedure for access and rectification in line with the aforementioned Regulation.

4. Related documents

Joint Controllership Arrangement with regard to the Union Product Database (UPD)
European Medicines Agency’s Data Protection Notice for the Union Product Database (UPD)

5. Changes since last revision

The main changes in this version of the policy are the addition of API for the general public and three new UPD fields in Annex A i.e. 'Product Grouping', 'Third Country Product Name' and 'QPPV email address'. Other editorial changes have been made to align with the chapter titles of the latest EMA policy template.
Amsterdam,

[Signature on file]

Emer Cooke
Executive Director
Annex A – Product data elements accessible by stakeholder group

RCUD = Read, Create, Update, Delete

Y/N = yes, no

The numbering reflects the field numbering in Annex II and III of the Implementing Regulation.

<table>
<thead>
<tr>
<th>UPD fields</th>
<th>Commission</th>
<th>Competent Authorities</th>
<th>Agency</th>
<th>Marketing Authorisation Holders</th>
<th>General Public</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Level 1</td>
<td>Level 2</td>
<td>Level 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>R C U D</td>
<td>R C U D</td>
<td>R C U D</td>
<td></td>
<td>R C U D</td>
</tr>
<tr>
<td>1. For all veterinary medicinal products</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.1 Product Domain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.2 Product Type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.3 Product Name</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.4 Active Substance(s)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.5 Strength/Composition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.6 Manufacturing Sites</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(. ) Operation type (for manufacturing site)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.7 Documents (SPC, PL, labelling, PuAR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Only for authorised veterinary medicinal products</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1 Dates of Placing on the Market</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5 The available information in the data fields depends on the authorisation procedure type of veterinary medicinal product (authorised, registered homeopathic, Art. 5(6) exemption or parallel traded product)

6 The document types are: Summary of Product Characteristics, package leaflet including labelling, public assessment report
## UPD fields

<table>
<thead>
<tr>
<th>UPD fields</th>
<th>Level 3</th>
<th>Level 2</th>
<th>Level 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commission</td>
<td>RCUD = Read, Create, Update, Delete</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Competent Authorities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agency</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marketing Authorisation Holders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General Public</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 2.2 Annual Volume of Sales

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>C</th>
<th>U</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.2 Annual Volume of Sales</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

### 2.3 Date of Availability Status

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>C</th>
<th>U</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.3 Date of Availability Status</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

### 2.4 Availability Status

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>C</th>
<th>U</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.4 Availability Status</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

### Product Grouping

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>C</th>
<th>U</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Grouping</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

### Third Country Product Name

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>C</th>
<th>U</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Third Country Product Name</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

### 3. For all veterinary medicinal products

#### 3.1 Permanent Identifier

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>C</th>
<th>U</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1 Permanent Identifier</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

#### 3.2 Product Identifier

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>C</th>
<th>U</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.2 Product Identifier</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

#### 3.3 Product Owner

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>C</th>
<th>U</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.3 Product Owner</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

#### 3.4 Authorisation Status

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>C</th>
<th>U</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.4 Authorisation Status</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

#### 3.5 Date of Authorisation Status Change

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>C</th>
<th>U</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.5 Date of Authorisation Status Change</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

#### 3.6 Route of Administration

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>C</th>
<th>U</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.6 Route of Administration</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

#### 3.7 Pharmaceutical Form

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>C</th>
<th>U</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.7 Pharmaceutical Form</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

#### 3.8 Target Species

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>C</th>
<th>U</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.8 Target Species</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

#### 3.9 ATCvet Code

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>C</th>
<th>U</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.9 ATCvet Code</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

#### 3.10 Withdrawal Period

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>C</th>
<th>U</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.10 Withdrawal Period</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

#### 3.11 PSMF Number

<table>
<thead>
<tr>
<th></th>
<th>R</th>
<th>C</th>
<th>U</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.11 PSMF Number</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

---

7 Information on Annual Volume of Sales refer to the following fields: volume of sales, reporting period (year-month), dose factor, species, estimated distribution across target species and comment which relates to any additional information provided by the Marketing Authorisation Holder.

8 New attribute introduced in UPD to support pharmacovigilance regulatory processes and other procedural aspects.
## UPD fields

<table>
<thead>
<tr>
<th>UPD fields</th>
<th>Level 3</th>
<th>Level 2</th>
<th>Level 1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Commission</td>
<td>Competent Authorities</td>
<td>Agency</td>
</tr>
<tr>
<td></td>
<td>R C U D</td>
<td>R C U D</td>
<td>R</td>
</tr>
<tr>
<td>3.12 PSMF Location</td>
<td>Y N N N</td>
<td>Y Y Y N</td>
<td>Y Y Y N</td>
</tr>
<tr>
<td>3.13 QPPV Name</td>
<td>Y N N N</td>
<td>Y Y Y N</td>
<td>Y Y Y N</td>
</tr>
<tr>
<td>3.14 QPPV Location</td>
<td>Y N N N</td>
<td>Y Y Y N</td>
<td>Y Y Y N</td>
</tr>
<tr>
<td>QPPV Email&lt;sup&gt;9&lt;/sup&gt;</td>
<td>Y N N N</td>
<td>Y Y Y N</td>
<td>Y Y Y N</td>
</tr>
<tr>
<td>3.15 Package Description</td>
<td>Y N N N</td>
<td>Y Y Y N</td>
<td>Y Y Y N</td>
</tr>
<tr>
<td>3.16 Legal Status for Supply</td>
<td>Y N N N</td>
<td>Y Y Y N</td>
<td>Y Y Y N</td>
</tr>
</tbody>
</table>

### 4. Procedural information for initial authorisation

| 4.1 Authorisation Procedure Type | Y N N N N | Y Y Y N | Y Y Y N | Y N N N N | Y N N N N |
| 4.2 Authorisation Procedure Number | Y N N N N | Y Y Y N | Y Y Y N | Y N N N N | Y N N N N |
| 4.3 Marketing Authorisation Date | Y N N N N | Y Y Y N | Y Y Y N | Y N N N N | Y N N N N |
| 4.4 Authorisation Country | Y N N N N | Y Y Y N | Y Y Y N | Y N N N N | Y N N N N |
| 4.5 Reference Member State | Y N N N N | Y Y Y N | Y Y Y N | Y N N N N | Y N N N N |
| 4.6 Member States Concerned | Y N N N N | Y Y Y N | Y Y Y N | Y N N N N | Y N N N N |
| 4.7 Legal Basis | Y N N N N | Y Y N N | Y Y N N | Y N N N N | Y N N N N |
| 4.8 Authorisation Number | Y N N N N | Y Y Y N | Y Y Y N | Y N N N N | Y N N N N |
| 4.9 Reference Product Identifier | Y N N N N | Y Y Y N | Y Y Y N | Y N N N N | Y N N N N |
| 4.10 Source Product Identifier | Y N N N N | Y Y Y N | Y Y Y N | Y N N N N | Y N N N N |
| (. ) Responsible Authority (Organisation) | Y N N N N | Y Y Y N | Y Y Y N | Y N N N N | Y N N N N |

### 5. Procedural information for post-authorisation changes

9 New attribute introduced in UPD to support pharmacovigilance regulatory processes and other procedural aspects.
## UPD fields

<table>
<thead>
<tr>
<th>UPD fields</th>
<th>Level 3</th>
<th>Level 2</th>
<th>Level 1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Commission</td>
<td>Competent Authorities</td>
<td>Agency</td>
</tr>
<tr>
<td></td>
<td>R</td>
<td>C</td>
<td>U</td>
</tr>
<tr>
<td>5.1 Submission Identifier</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>5.2 Authorisation Procedure Number</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>5.3 Responsible Authority</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>5.4 Variation Classification Code</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>5.5 Submission Comment</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>5.6 Date of Implementation</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>5.7 Date of Submission</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>5.8 Decision</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>5.9 Date of Decision</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>5.10 Author of Decision</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>6.1 Source Wholesale Distributor</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>6.2 Destination Wholesale Distributor</td>
<td>Y</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

(a) Marketing authorisation holders can request the update of some of these fields, by the relevant Competent Authorities, via variation that does not require assessment or variation requiring assessment.

(b) Only visible for batch release manufacturing sites.

(c) For mutual recognition (MRP), decentralised (DCP) and subsequent recognition procedures, the reference member state (RMS) is responsible for creating or updating the English version of the documents.

(d) Only visible to the marketing authorisation holder that owns that veterinary medicinal product.

(e) Only visible to the marketing authorisation holder that owns that veterinary medicinal product, except for batch release manufacturing sites.